Action-Based Learning Projects:
MAP & Consulting Studio
Communication dependent technology is advancing rapidly leaving business decision makers struggling to establish a clear business case for adoption individual technologies and/or combined technologies. Smaller enterprises lack the depth of technical staff to dedicate time to analyzing new technology tools and the result is these companies losing comparative cost efficiency with companies that are able to make these analysis.
Pancreatic cancer (PDAC) is projected to become the second deadliest cancer in the US by 2030. Diagnosis is made in most cases at an advanced stage when cancer has already spread; 52% of patients present with distant disease at the time of diagnosis, while 30% of the cases exhibit regional disease. Early diagnosis is often prevented by suboptimal diagnostic capabilities and the subclinical symptoms associated with localized pancreatic cancer.
The primary limitation in the development of an early-stage PDAC diagnostic is the lack of a sufficiently specific and sensitive biomarker. To overcome this impediment and address the unmet critical need of an early-stage PDAC diagnostic, Xerient, in collaboration with MD Anderson and Caerus Therapeutics, initiated the development of the XR10 and X15 diagnostic antibodies for PDAC.
By specifically measuring a unique cancer-associated glycoprotein, Xerient’s proprietary antibodies - XR10/XR15, can detect malignancy-sourced overexpression of CEACAM5/6, a potential biomarker for many cancers. This can offer, for the first time, the early detection of PDAC in at risk populations, allowing for an earlier diagnosis and an opportunity to improve the 5-year survival rate, currently measured at only 11.5% overall and at only 3% for patients with distant disease. A sensitive, PDAC-specific assay can also be a more valuable tool for measuring general tumor burden. This will be particularly useful in quantifying responses to chemotherapy, immunotherapy, or cytoreductive surgery, which are currently only quantifiable using an inadequate serum diagnostic assay (i.e., CA 19-9). The company is in advance stages of development and aim at a regulatory approval for the diagnostic product by mid-2024.
To ensure commercial success the company seeks to work with a Ross School MAP team on its strategic planning, emphasizing alliance-forming, licensing and M&A opportunities.
Manufacturing - Lean Focus
Evaluate the current process for a mobile medical trailer manufacturer and create a current state value stream map . Identify waste, poor processes, and bottlenecks within the process and recommend opportunities for improvement. Create a future state VSM based on improvements.
DeepHow is an AI-powered learning platform that bridges the skills gap in manufacturing, service, repair, and skilled work through interactive how-to videos. DeepHow would like assistance with a data-driven, go-to-market strategy to maximize existing and new product growth via SEO optimization, tapping into the content creator economy, and leveraging AI & meta-data.
